详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Pathogenesis and treatment of multiple myeloma.

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Hematology and Institute of Hematology, State Key Laboratory of Biotherapy and Cancer Center,West China Hospital, Sichuan University, Chengdu, Sichuan, China

出处：

DOI：

关键词： multiple myeloma nanomedicine pathogenesis treatment

摘要：

Multiple myeloma (MM) is the second-ranking malignancy in hematological tumors. The pathogenesis of MM is complex with high heterogeneity, and the development of the disease is a multistep process. Chromosomal translocations, aneuploidy, genetic mutations, and epigenetic aberrations are essential in disease initiation and progression. The correlation between MM cells and the bone marrow microenvironment is associated with the survival, progression, migration, and drug resistance of MM cells. In recent decades, there has been a significant change in the paradigm for the management of MM. With the development of proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, chimeric antigen receptor T-cell therapies, and novel agents, the survival of MM patients has been significantly improved. In addition, nanotechnology acts as both a nanocarrier and a treatment tool for MM. The properties and responsive conditions of nanomedicine can be tailored to reach different goals. Nanomedicine with a precise targeting property has offered great potential for drug delivery and assisted in tumor immunotherapy. In this review, we summarize the pathogenesis and current treatment options of MM, then overview recent advances in nanomedicine-based systems, aiming to provide more insights into the treatment of MM.© 2022 The Authors. MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

无

最新[2023]版：

大类 | 3 区医学

小类 | 3 区医学：研究与实验

第一作者：

第一作者机构： [1]Department of Hematology and Institute of Hematology, State Key Laboratory of Biotherapy and Cancer Center,West China Hospital, Sichuan University, Chengdu, Sichuan, China

共同第一作者：

通讯作者：

通讯机构： [1]Department of Hematology and Institute of Hematology, State Key Laboratory of Biotherapy and Cancer Center,West China Hospital, Sichuan University, Chengdu, Sichuan, China [*1]Department of Hematology and Institute of Hematology, State Key Laboratory of Biotherapy and Cancer Center,West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]BMI1 regulates multiple myeloma-associated macrophage's pro-myeloma functions. [2]Treatment attrition rates and relevant risk factors in multiple myeloma: A real-world study in China [3]脂质体多柔比星对初治多发性骨髓瘤疗效及不良反应评估 [4]Advances in research on potential inhibitors of multiple myeloma [5]Melphalan-loaded methoxy poly(ethylene glycol)-poly(d,l-lactide) copolymer nanomicelles in the treatment of multiple myeloma [6]Heme oxygenase-1 attenuates the inhibitory effect of bortezomib against the APRIL-NF-κB-CCL3 signaling pathways in multiple myeloma cells: Corelated with bortezomib tolerance in multiple myeloma. [7]多发性骨髓瘤疾病全周期健康管理 [8]High level of soluble interleukin-2 receptor in serum predicts treatment resistance and poor progression-free survival in multiple myeloma [9]An update on Becker's nevus: Pathogenesis and treatment [10]Therapeutic effects of CSF1R-blocking antibodies in multiple myeloma.